In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants might be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In Phase C, https://andersonbqcoe.blogpayz.com/32001975/details-fiction-and-abbv-744-in-acute-myeloid-leukemia-aml